Gilead to buy cancer drugmaker Immunomedics in $21 billion deal – CNBC

The deal will provide Gilead access to Immunomedics’ cancer treatment drug called Trodelvy, an FDA-approved treatment for metastatic triple-negative breast cancer.
Read More

LEAVE A REPLY

Please enter your comment!
Please enter your name here